https://www.selleckchem.com/products/Rolipram.html
In the recent CREDENCE trial, canagliflozin reduced renal endpoints by 34% and end-stage renal disease by 32%. Furthermore, in the recent DAPA-HF trial, dapagliflozin decreased hospitalization for HF/cardiovascular death by 26%, and total death by 17%, in patients with HF with reduced ejection fraction, irrespective of diabetes or non-diabetes. The beneficial effects of SGLT-2 inhibitors in CKD and HF are complementary to the effects of statins. The introduction of SGLT-2 inhibitors in clinical practice is the second revolution in card
Like
Comment
Share
